Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3783-3790

  Jeruss, Jacqueline S ^a,b   Sturgis, Charles D ^b,c   Rademaker, Alfred W ^b   Woodruff, Teresa K ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OT Hogan 4 150 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INVOLUTION; LACTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ACTIVIN RECEPTORS; ACTIVINS; BREAST; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; REFERENCE VALUES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATORS;

EID: 0038756352     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Dumont, N., and Arteaga, C. L. Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β. Breast Cancer Res. Treat., 2: 125-132, 2000.
2. Lebrun, J. J., and Vale, W. W. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol. Cell. Biol., 17: 1682-1691, 1997.
3. Massague, J. TGF-β signal transduction. Annu. Rev. Biochem., 67: 753-791, 1998.
4. Woodruff, T. K. Regulation of cellular and system function by activin. Biochem. Pharmacol., 55: 953-963, 1998.
5. Woodruff, T. K., and Mather, J. P. Inhibin, activin and the female reproductive axis. Annu. Rev. Physiol., 57: 219-244, 1995.
6. Risbridger, G. P., Schmitt, J. F., and Robertson, D. M. Activins and inhibins in endocrine and other tumors. Endocr. Rev., 22: 836-858, 2001.
7. Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J., Heldin, C. H., Miyazono, K., and ten Dijke, P. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J., 16: 5353-5362, 1997.
8. Whitman, M. Smads and early developmental signaling by the TGFβ superfamily. Genes Dev., 12: 2445-2462, 1998.
9. Yue, J., and Mulder, K. M. Requirement of Ras/MAPK pathway activation by transforming growth factor β for transforming growth factor β 1 production in a Smad-dependent pathway. J. Biol. Chem., 275: 30765-73, 2000.
10. Yue, J., and Mulder, K. M. Transforming growth factor-β signal transduction in epithelial cells. Pharmacol. Ther., 91: 1-34, 2001.
11. Attisano, L., and Tuen Lee-Hoeflich, S. The Smads, Genome Biol. 2: 3010.1-3010.8, 2001.
12. Shi, Y., Hata, A., Lo, R. S., Massague, J., and Pavletich, N. P. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (Lond.), 388: 87-93, 1997.
13. Lewis, K. A., Gray, P. C., Blount, A. L., MacConell, L. A., Wiater, E., Bilezikjian, L. M., and Vale, W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature (Lond.), 404: 411-414, 2000.
14. Di Loreto, C., Reis, F. M., Cataldi, P., Zuiani, C., Luisi, S., Beltrami, C. A., and Petraglia, F. Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Eur. J. Endocrinol., 141: 190-194, 1999.
15. Liu, Q. Y., Niranjan, B., Gomes, P., Gomm, J. J., Davies, D., Coombes, R. C., and Buluwela, L. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res., 56: 1155-1163, 1996.
16. Ying, Y. S., Zhang, Z., Huang, G., and Hsieh, F. C. Inhibin/activin subunits and actvin receptors in human breast cell lines and lactating rat mammary glands. Int. J. Oncol., 7: 481-485, 1995.
17. Robinson, G. W., and Hennighausen, L. Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions. Development, 124: 2701-2708, 1997.
18. Gorska, A. E., Joseph, H., Derynck, R., Moses, H. L., and Serra, R. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ., 9: 229-238, 1998.
19. Derynck, R., Akhurst, R. J., and Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129, 2001.
20. Kalkhoven, E., Roelen, B. A., de Winter, J. P., Mummery, C. L., van den Eijnden-van Raaij, A. J., van der Saag, P. T., and van der Burg, B. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ., 6: 1151-1161, 1995.
21. Ying, S. Y., and Zhang, Z. Expression and localization of inhihin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Res. Treat., 37: 151-160, 1996.
22. Wakefield, L. M., Piek, E., and Bottinger, E. P. TGF-β signaling in mammary gland development and tumorigenesis. J. Mamm. Gland Biol. Neoplasia, 6: 67-82, 2001.
23. Xie, W., Mertens, J. C., Reiss, D. J., Rimm, D. L., Camp, R. L., Haffty, B. G., and Reiss, M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res., 62: 497-505, 2002.
24. Jeruss, J. S., Santiago, J. S., and Woodruff, T. K. Localization of activin and inhibin subunits, receptors and Smads in the mouse mammary gland. Mol. Cell. Endocrinol., 203: 185-196, 2003.
25. Daniel, C. W., Robinson, S., and Silberstein, G. B. The role of TGF-β in patterning and growth of the mammary ductal tree. J. Mamm. Gland Biol. Neoplasia, 1: 331-341, 1996.
26. Nguyen, A. V., and Pollard, J. W. Transforming growth factor β3 induces cell death during the first stage of mammary gland involution. Development, 127: 3107-3118, 2000.
27. de Winter, J. P., Roelen, B. A., ten Dijke, P., van der Burg, B., and van den Eijnden-van Raaij, A. J. DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene, 14: 1891-1899, 1997.
28. Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massague, J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature (Lond.), 383: 832-836, 1996.
29. Azhar, M. Non-redundant tumour supressor functions of transforming growth factor β in breast cancer, J. Biosci., 26: 9-12, 2001.
30. Gobbi, H., Arteaga, C. L., Jensen, R. A., Simpson, J. F., Dupont, W. D., Olson, S. J., Schuyler, P. A., Plummer, W. D., Jr., and Page, D. L. Loss of expression of transforming growth factor β type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology, 36: 168-177, 2000.
31. Pinder, S. E., Murray, S., Ellis, I. O., Trihia, H., Elston, C. W., Gelber, R. D., Goldhirsch, A., Lindtner, J., Cortes-Funes, H., Simoncini, E., Byrne, M. J., Golouh, R., Rudenstam, C. M., Castiglione-Gertsch, M., and Gusterson, B. A. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer (Phila.), 83: 1529-1539, 1998.
32. Connolly, J. L., Fetchner, R. E., Kempson, R. L., Livolsi, V. A., Page, D. L., Patchefsky, A. A., and Silverberg, S. G. Recommendations for the reporting of breast carcinoma. Hum. Pathol., 27: 220-222, 1996.
33. Ball, E. M., and Risbridger, G. P. Activins as regulators of branching morphogenesis. Dev. Biol., 238: 1-12, 2001.
34. Cocolakis, E., Lemay, S., Ali, S., and Lebrun, J. J. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J. Biol. Chem., 276: 18430-6, 2001.
35. Reis, F. M., Cobellis, L., Tameirao, L. C., Anania, G., Luisi, S., Silva, I. S., Gioffre, W., Di Blasio, A. M., and Petraglia, F. Serum and tissue expression of activin a in postmenopausal women with breast cancer. J. Clin. Endocrinol. Metab., 87: 2277-2282, 2002.
36. Inman, G. J., Nicolas, F. J., and Hill, C. S. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol. Cell., 10: 283-294, 2002.
37. Kretzschmar, M., Doody, J., Timokhina, I., and Massague, J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev., 13: 804-816, 1999.
38. Kretzschmar, M. Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer. Breast Cancer Res. Treat., 2: 107-115, 2000.
39. Luo, K., Stroschein, S. L., Wang, W., Chen, D., Martens, E., Zhou, S., and Zhou, Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Genes Dev., 13: 2196-206, 1999.
40. Stroschein, S. L., Wang, W., Zhou, S., Zhou, Q., and Luo, K. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science (Wash. DC), 286: 771-774, 1999.
41. Kurokawa, M., Mitani, K., Imai, Y., Ogawa, S., Yazaki, Y., and Hirai, H. The t(3;21) fusion product. AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood, 92: 4003-4012, 1998.
42. Chen, C. R., Kang, Y., Siegel, P. M., and Massague, J. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell, 110: 19-32, 2002.
43. Chen, C. R., Kang, Y., and Massague, J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc. Natl. Acad. Sci. USA, 98: 992-999, 2001.
44. Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Ueno, Y., Yamashita, H., Nomura, K., Ichiguchi, O., and et al. Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer. Gan To Kagaku Ryoho, 18: 2271-2275, 1991.
45. Metzger, R. J., and Krasnow, M. A. Genetic control of branching morphogenesis. Science (Wash. DC), 284: 1635-1639, 1999.
46. Cancilla, B., Jarred, R. A., Wang, H., Mellor, S. L., Cunha, G. R., and Risbridger, G. P. Regulation of prostate branching morphogenesis by activin A and follistatin. Dev. Biol., 237: 145-158, 2001.
47. Frkovic-Grazio, S., and Bracko, M. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J. Clin. Pathol., 55: 88-92, 2002.
48. Tobin, S. W., Brown, M. K., Douville, K., Payne, D. C., Eastman, A., and Arrick, B. A. Inhibition of transforming growth factor β signaling in MCF-7 cells results in resistance to tumor necrosis factor α: a role for Bcl-2. Cell Growth Differ., 12: 109-117, 2001.
49. Donovan, J., and Slingerland, J. Transforming growth factor-β and breast cancer: cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Res., 2: 116-124, 2000.
50. Robinson, S. D., Silberstein, G. B., Roberts, A. B., Flanders, K. C., and Daniel, C. W. Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary gland development. Development. 113: 867-878, 1991.
51. Fisher, E. R., Sass, R., and Fisher, B. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer (Phila.), 53: 712-723, 1984.
52. Rosen, P. P., Groshen, S., Kinne, D. W., and Norton, L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J. Clin. Oncol., 11: 2090-100, 1993.
53. nd Ed., pp. 63-84. London: Martin Dunitz, 2001.
54. Costa, S. D., Lange, S., Klinga, K., Merkle, E., and Kaufmann, M. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer-results of the analysis of 670 patients with 11 years of follow-up. Eur. J. Cancer, 38: 1329-1334, 2002.
55. Brattain, M. G., Ko, Y., Banerji, S. S., Wu, G., and Willson, J. K. Defects of TGF-β receptor signaling in mammary cell tumorigenesis. J. Mamm. Gland Biol. Neoplasia, 1: 365-372, 1996.
56. Sun, L., Wu, G., Willson, J. K., Zborowska, E., Yang, J., Rajkarunanayake, I., Wang, J., Gentry, L. E., Wang, X. F., and Brattain, M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem., 269: 26449-26455, 1994.